Falcon Genomics, Inc.

An eye on functional genomics as a tool for cancer diagnostics and therapeutics.
Home
News
The Cancer BioChip System
Officers
Presentations
Founders
Contact Us
CBCS services

Mission

The goal of Falcon Genomics, Inc. is to provide cutting edge technologies for the accurate diagnosis of cancer patients and the personalized formulation of therapeutic strategies.

Technology Platform
Falcon Genomics' patented technology platform, the Cancer BioChip System (CBCS™) identifies, in a high-throughput three-dimensional fashion, compounds that are required for anchorage-independent growth of patient cells, a hallmark of cellular transformation. Potential compounds include silencing RNA libraries that contain inhibitors for every gene in the human genome.

Technology Applications

The CBCS™ can be initially used for high-throughput cancer therapeutic target identification and validation. Through future clinical trials, the CBCS™ can be developed into a diagnostic tool that can be used to guide patient-specific cancer therapies.

Recent News

November 16, 2009

Dr. Rula Abbud-Antaki presents Falcon Genomics' Company Presentation at "Biotech 2009, PA Convention Center, Philadelphia, PA".

May 26, 2009

Falcon Genomics, Inc. receives U.S. Patent # 7,537,913 with claims covering the Company's Cancer BioChip System (CBCS) for the identification and validation of potential cancer targets in a high-throughput in vitro setting with great clinical translational potential.

http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/05-28-2009/0005034230&EDATE

February 19, 2009 

Falcon Genomics, Inc. co-sponsors the "6th Annual Conference on Cancer Drugs Research and Development" Philadelphia, PA.

 

Dr. Rula Abbud-Antaki presents at "6th Annual Conference on Cancer Drugs Research and Development" Philadelphia, PA.

Presentation Title: The Cancer BioChip System: A tool for custon-tailored cancer diagnosis and therapy. http://www.gtcbio.com/conferenceDetails.aspx?id=143

Clients

Pharmaceutical companies and research insitutions seeking a rapid and efficient platform for the identification of cancer targets in a setting that mimics the in-vivo milieu.

 

Please contact Dr. Rula Abbud-Antaki for further information: rabbud@falcongenomics.com

Address:

160 North Craig Street, Suite 222, Pittsburgh, PA 15213, Phone: 412-802-6236, Fax: 412-802-7048, e-mail: falcongenomics@verizon.net